A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation. Estudio multicentrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutanea para el tratamiento del estrenimiento inducido por opiaceos

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation. Estudio multicentrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutanea para el tratamiento del estrenimiento inducido por opiaceos

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2012

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2012 Actual end date 1 Jun 2009 added as reported by European Clinical Trials Database.
    • 01 May 2012 Actual end date 1 Jun 2009 added as reported by European Clinical Trials Database.
    • 28 Apr 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top